Welcome to our dedicated page for Herbalife SEC filings (Ticker: HLF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Herbalife Ltd. filings document the regulatory record of a Cayman Islands health and wellness company with common shares listed on the New York Stock Exchange under HLF. Form 8-K reports cover quarterly and annual financial results, Regulation FD materials, material definitive agreements, senior secured notes due 2033, and amendments to secured credit facilities involving company subsidiaries.
Proxy materials cover annual general meeting procedures, shareholder voting matters, and governance. The filings also describe capital-structure subjects, security registration details, and formal disclosures related to the company’s products, network marketing program, and legal or regulatory risk areas.
Herbalife Ltd. Executive Chairman Michael Johnson reported an amended insider filing reflecting equity awards granted on February 25, 2026. He was granted 399,619 stock appreciation rights and 72,689 restricted stock units under the Amended and Restated 2023 Stock Incentive Plan. Both the SARs and RSUs vest in two equal installments, 50% on February 25, 2027 and 50% on February 25, 2028, contingent on continued service. The amendment states it was filed solely to correct a previously reported exercise price; no other information from the original Form 4 was changed.
HERBALIFE LTD. Chief Legal Officer Henry C. Wang reported an amended Form 4 reflecting a grant of 33,301 stock appreciation rights. The amendment corrects a previously reported exercise price of $10.51. These SARs were granted under the company’s Amended and Restated 2023 Stock Incentive Plan and will vest in three equal installments on February 25, 2027, February 25, 2028, and February 25, 2029, subject to continued service.
HERBALIFE LTD. President Robert Levy reported an amended insider transaction reflecting a grant of stock appreciation rights. The Form 4/A shows an acquisition of 33,301 stock appreciation rights at an exercise price of $0.00 per right, classified as a grant or award.
The amendment states it was filed solely to correct the previously reported exercise price, which had been shown as $10.51, with no other changes to the original filing. These stock appreciation rights were granted under the Herbalife Ltd. Amended and Restated 2023 Stock Incentive Plan and will vest in three equal installments on February 25, 2027, February 25, 2028, and February 25, 2029, subject to Mr. Levy’s continued service.
HERBALIFE LTD. Chief Operating Officer Troy Hicks filed an amended insider report reflecting a prior grant of 33,301 stock appreciation rights (SARs). The amendment is solely to correct the exercise price previously reported as $10.51; all other details remain unchanged. The SARs were granted under the Amended and Restated 2023 Stock Incentive Plan and will vest in three equal installments on February 25, 2027, 2028, and 2029, subject to his continued service.
HERBALIFE LTD. Chief Executive Officer Stephan Paulo Gratziani reported an amended Form 4 reflecting a prior grant of stock appreciation rights. The amendment is filed solely to correct the exercise price, which had previously been reported as $10.51. The CEO holds 215,033 stock appreciation rights granted on February 25, 2026, under the Amended and Restated 2023 Stock Incentive Plan. These rights vest in three equal installments on February 25, 2027, February 25, 2028, and February 25, 2029, contingent on continued service, and represent non-cash equity-based compensation rather than an open-market share purchase or sale.
LEVY ROBERT reported acquisition or exercise transactions in this Form 4 filing.
HERBALIFE LTD. reported that President Robert Levy received a grant of 33,301 stock appreciation rights (SARs) on February 25, 2026 under the Herbalife Ltd. Amended and Restated 2023 Stock Incentive Plan. These derivative awards were granted at a price of $0.00 per right as part of his compensation.
The SARs will vest in three equal installments, with one-third vesting on each of February 25, 2027, February 25, 2028, and February 25, 2029, subject to his continued service through each vesting date. Following this grant, he directly holds 33,301 SARs.
Lamberti Frank reported acquisition or exercise transactions in this Form 4 filing.
Herbalife Ltd. Chief Commercial Officer Frank Lamberti received a grant of 40,437 stock appreciation rights (SARs) on February 25, 2026 under the Herbalife Ltd. Amended and Restated 2023 Stock Incentive Plan. These SARs were awarded at a price of $0.00 per right.
The SARs vest in three equal installments, with one-third vesting on February 25, 2027, one-third on February 25, 2028, and the final one-third on February 25, 2029, subject to Mr. Lamberti’s continued service through each vesting date. Following this grant, he holds 40,437 SARs directly.
JOHNSON MICHAEL reported acquisition or exercise transactions in this Form 4 filing.
HERBALIFE LTD. Executive Chairman Michael Johnson reported equity awards rather than open-market trades. On February 25, 2026, he was granted 399,619 stock appreciation rights at $0.00 per share and 72,689 restricted stock units representing common stock.
Both the RSUs and SARs were granted under the company’s stock incentive plan and vest in two equal installments: 50% on February 25, 2027 and 50% on February 25, 2028, subject to continued service. Following these awards, his direct common stock holdings reported total 887,415 shares.
Hicks Troy reported acquisition or exercise transactions in this Form 4 filing.
Herbalife Ltd.'s Chief Operating Officer, Troy Hicks, received a grant of 33,301 stock appreciation rights (SARs) on February 25, 2026. These SARs were issued at a price of $0.00 per right and increase in value if the company’s stock price rises.
The award was granted under the Herbalife Ltd. Amended and Restated 2023 Stock Incentive Plan. The SARs will vest in three equal installments on February 25, 2027, February 25, 2028, and February 25, 2029, as long as Hicks continues in service through each vesting date.
Gratziani Stephan Paulo reported acquisition or exercise transactions in this Form 4 filing.
HERBALIFE LTD. Chief Executive Officer Stephan Paulo Gratziani reported receiving a grant of 215,033 stock appreciation rights on February 25, 2026. These rights were granted under the Herbalife Ltd. Amended and Restated 2023 Stock Incentive Plan as equity-based compensation.
The stock appreciation rights will vest in one-third increments on February 25, 2027, February 25, 2028, and February 25, 2029, and each installment is subject to his continued service with the company through the applicable vesting date.